Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Next Previous
Trial Profile

Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Balstilimab (Primary) ; Botensilimab (Primary)
  • Indications Adenocarcinoma; Anal cancer; Bladder cancer; Breast cancer; Cervical cancer; Duodenal cancer; Endometrial cancer; Gastric cancer; Head and neck cancer; Male breast cancer; Merkel cell carcinoma; Oesophageal cancer; Ovarian cancer; Prostate cancer; Sarcoma; Squamous cell cancer; Triple negative breast cancer
  • Focus Therapeutic Use
  • Acronyms NEOASIS

Most Recent Events

  • 30 Apr 2025 Results assessing safety and efficacy data from the safety run-in cohorts presented at the 116th Annual Meeting of the American Association for Cancer Research
  • 28 Apr 2025 According to an Agenus media release, data from this study were presented in an oral session at the American Association for Cancer Research (AACR) Annual Meeting.
  • 28 Apr 2025 Results presented in an Agenus media release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top